Clinical use of exhaled biomarkers in COPD

Exhaled breath analysis holds great promise as a diagnostic and investigative tool in COPD and is a new and rapidly expanding field of research in pulmonary disease. Generally speaking, exhaled breath analysis focuses on two areas: measurement of exhaled nitric oxide (ENO) and the detection of biomarkers in exhaled breath condensate (EBC). ENO measurement may not be as useful in COPD as in other pulmonary diseases, such as asthma, due to the lower levels of ENO found in COPD, although this is an area of ongoing research. Analysis of EBC for proinflammatory biomarkers is an area of great promise but its true value will not be realized until methods of collecting and analyzing EBC have been standardized. Once this is done, biomarkers detected in EBC may assist in the diagnosis of COPD, identification of preclinical disease, phenotyping of COPD patients, evaluation of response to therapies and defining the prognosis of individual patients. Identification of novel inflammatory mediators in EBC may cast new light on the pathogenesis of COPD and identify new therapeutic targets, which are badly needed in this disease.

[1]  W. Bailey,et al.  Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: an NHLBI workshop report. , 2006, American journal of respiratory and critical care medicine.

[2]  D. Postma,et al.  Pulmonary biomarkers in chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[3]  A. Kraneveld,et al.  A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation , 2006, Nature Medicine.

[4]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[5]  D. Hui,et al.  Exhaled breath condensate levels of 8-isoprostane, growth related oncogene alpha and monocyte chemoattractant protein-1 in patients with chronic obstructive pulmonary disease. , 2006, Respiratory medicine.

[6]  P. J. Barnes,et al.  Exhaled breath condensate: methodological recommendations and unresolved questions , 2005, European Respiratory Journal.

[7]  P. Montuschi.  Exhaled breath condensate analysis in patients with COPD. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[8]  J. Cowan,et al.  Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. , 2005, The New England journal of medicine.

[9]  E. Ingenito,et al.  The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years. , 2005, American journal of respiratory cell and molecular biology.

[10]  A. Aceto,et al.  Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. , 2005, Pulmonary pharmacology & therapeutics.

[11]  R. Shaker,et al.  A simple method for estimating respiratory solute dilution in exhaled breath condensates. , 2003, American journal of respiratory and critical care medicine.

[12]  P. Barnes,et al.  High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. , 2003, Respiratory medicine.

[13]  A. M. Houghton,et al.  Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. , 2003, The American journal of pathology.

[14]  Konstantinos Kostikas,et al.  Oxidative stress in expired breath condensate of patients with COPD. , 2003, Chest.

[15]  S. Spencer,et al.  Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.

[16]  M. Corradi,et al.  Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[17]  W. van Beurden,et al.  Effects of Inhaled Corticosteroids with Different Lung Deposition on Exhaled Hydrogen Peroxide in Stable COPD Patients , 2003, Respiration.

[18]  P. Barnes,et al.  Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD , 2003, Thorax.

[19]  J. Morrow,et al.  The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[20]  Brigit VanGraafeiland,et al.  National Asthma Education and Prevention Program. , 2002, The Nurse practitioner.

[21]  Konstantinos Kostikas,et al.  pH in expired breath condensate of patients with inflammatory airway diseases. , 2002, American journal of respiratory and critical care medicine.

[22]  S. Matalon,et al.  Killing of Klebsiella pneumoniae by human alveolar macrophages. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[23]  J. Hoidal,et al.  Future research directions in chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[24]  M. Gare,et al.  Dilution of respiratory solutes in exhaled condensates. , 2002, American journal of respiratory and critical care medicine.

[25]  N. Zamel,et al.  Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effects of inhaled beclomethasone. , 2001, American journal of respiratory and critical care medicine.

[26]  P. Montuschi,et al.  Exhaled carbon monoxide and nitric oxide in COPD. , 2001, Chest.

[27]  D. Nowak,et al.  Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. , 2001, Respiratory medicine.

[28]  L. Janssen.  Isoprostanes: an overview and putative roles in pulmonary pathophysiology. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[29]  D. Nowak,et al.  Exhalation of H2O2 and thiobarbituric acid reactive substances (TBARs) by healthy subjects. , 2001, Free radical biology & medicine.

[30]  N. Lazzeri,et al.  Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. , 2000, American journal of respiratory and critical care medicine.

[31]  N. Ambrosino,et al.  Production of endogenous nitric oxide in chronic obstructive pulmonary disease and patients with cor pulmonale. Correlates with echo-Doppler assessment. , 2000, American journal of respiratory and critical care medicine.

[32]  A. Aceto,et al.  Validation of a new technique to assess exhaled hydrogen peroxide: results from normals and COPD patients. , 2000, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[33]  J. Morrow,et al.  Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. , 2000, Free radical biology & medicine.

[34]  A. Agustí,et al.  Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. , 1999, The European respiratory journal.

[35]  M. Corradi,et al.  Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease , 1999, Thorax.

[36]  D. Postma,et al.  Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease , 1999, Thorax.

[37]  T. Pietras,et al.  Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. , 1999, Respiratory medicine.

[38]  J. Morrow,et al.  The Isoprostanes: Unique Bioactive Products of Lipid Peroxidation , 1997, Journal of Biomedical Science.

[39]  N. Ambrosino,et al.  Endogenous nitric oxide in patients with stable COPD: correlates with severity of disease , 1998, Thorax.

[40]  W. Maziak,et al.  Exhaled nitric oxide in chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[41]  S. Shapiro,et al.  Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. , 1997, Science.

[42]  A Bast,et al.  Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. , 1997, American journal of respiratory and critical care medicine.

[43]  J. Bousquet,et al.  Corticosteroid reversibility in COPD is related to features of asthma. , 1997, American journal of respiratory and critical care medicine.

[44]  K. Aben,et al.  Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[45]  M. Yacoub,et al.  8-Epi-PGF2 alpha, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro. , 1996, American journal of respiratory and critical care medicine.

[46]  D. Yates,et al.  Acute and chronic effects of cigarette smoking on exhaled nitric oxide. , 1995, American journal of respiratory and critical care medicine.

[47]  G. O'Connor,et al.  Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. , 1995, American journal of respiratory and critical care medicine.

[48]  S. Matalon,et al.  Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury. , 1994, The Journal of clinical investigation.

[49]  J. Stamler,et al.  The biology of nitrogen oxides in the airways. , 1994, American journal of respiratory and critical care medicine.

[50]  J. Morrow,et al.  Airway and vascular effects of 8-epi-prostaglandin F2 alpha in isolated perfused rat lung. , 1993, Journal of applied physiology.

[51]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.